Log in

OTCMKTS:SEOVFSernova Stock Price, Forecast & News

0.00 (-2.44 %)
(As of 07/14/2020 04:00 PM ET)
Today's Range
Now: $0.19
50-Day Range
MA: $0.19
52-Week Range
Now: $0.19
Volume7,475 shs
Average Volume28,189 shs
Market Capitalization$36.92 million
P/E RatioN/A
Dividend YieldN/A
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch and associated technologies, including therapeutic cells and local immune protection. The company is developing a Cell Pouch system that is in Phase I/II clinical trial for the treatment of type-1 diabetes. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells for the treatment of chronic diseases, such as hemophilia A and thyroid diseases. Sernova Corp. is headquartered in London, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A
Book Value$0.02 per share


Net Income$-2,990,000.00


Market Cap$36.92 million
Next Earnings Date10/5/2020 (Estimated)
OptionableNot Optionable

Receive SEOVF News and Ratings via Email

Sign-up to receive the latest news and ratings for SEOVF and its competitors with MarketBeat's FREE daily newsletter.

Sernova (OTCMKTS:SEOVF) Frequently Asked Questions

How has Sernova's stock been impacted by COVID-19 (Coronavirus)?

Sernova's stock was trading at $0.1092 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SEOVF stock has increased by 72.4% and is now trading at $0.1883. View which stocks have been most impacted by Coronavirus.

When is Sernova's next earnings date?

Sernova is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Sernova.

Has Sernova been receiving favorable news coverage?

Press coverage about SEOVF stock has been trending extremely negative on Wednesday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sernova earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. View the latest news about Sernova.

Who are some of Sernova's key competitors?

Who are Sernova's key executives?

Sernova's management team includes the following people:
  • Dr. Philip M. Toleikis, Pres, CEO & Director
  • Mr. Sean P. Hodgins CPA, CA, (Illinois), Chief Financial Officer
  • Mr. Douglas Maret, Chief Science Officer

What is Sernova's stock symbol?

Sernova trades on the OTCMKTS under the ticker symbol "SEOVF."

How do I buy shares of Sernova?

Shares of SEOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sernova's stock price today?

One share of SEOVF stock can currently be purchased for approximately $0.19.

How big of a company is Sernova?

Sernova has a market capitalization of $36.92 million.

What is Sernova's official website?

The official website for Sernova is www.sernova.com.

How can I contact Sernova?

Sernova's mailing address is 700 COLLIP CIRCLE SUITE 114, LONDON A6, N6G 4X8. The company can be reached via phone at 519-858-5184 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.